Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
The Lancet. Oncology|September 21, 2020
Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targetsTyler Stewart, Karin Finberg, Zenta Walther, et al.
Physical Review Letters|March 25, 2017
Photon Statistics of Propagating Thermal MicrowavesJ Goetz, S Pogorzalek, F Deppe, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patientsJ P Eder, A D Elias, L Ayash, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionJ G Supko, T J Lynch, J W Clark, et al.
JCO Precision Oncology|January 7, 2022
Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal SarcomasJoseph P Eder, Deborah B Doroshow, Khanh T Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancerJ P Eder, K Antman, W Peters, et al.
Cancer Treatment Reports|February 1, 1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experienceK Antman, J P Eder, A Elias, et al.
Journal of the National Cancer Institute|April 7, 1993
Intensive combined modality therapy for limited-stage small-cell lung cancerA D Elias, L Ayash, E Frei, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
Cancer Research|February 15, 1991
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinomaB A Teicher, T S Herman, J Tanaka, et al.
The Lancet. Oncology|September 21, 2020
Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targetsTyler Stewart, Karin Finberg, Zenta Walther, et al.
Physical Review Letters|March 25, 2017
Photon Statistics of Propagating Thermal MicrowavesJ Goetz, S Pogorzalek, F Deppe, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignanciesC A Bunnell, J G Supko, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patientsJ P Eder, A D Elias, L Ayash, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusionJ G Supko, T J Lynch, J W Clark, et al.
JCO Precision Oncology|January 7, 2022
Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal SarcomasJoseph P Eder, Deborah B Doroshow, Khanh T Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1986
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancerJ P Eder, K Antman, W Peters, et al.
Cancer Treatment Reports|February 1, 1987
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experienceK Antman, J P Eder, A Elias, et al.
Journal of the National Cancer Institute|April 7, 1993
Intensive combined modality therapy for limited-stage small-cell lung cancerA D Elias, L Ayash, E Frei, et al.
Pageof 12